TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway

Prasanna Vasudevan Iyengar, Dieuwke L. Marvin, Dilraj Lama, Tuan Zea Tan, Sudha Suriyamurthy, Feng Xie, Maarten van Dinther, Hailiang Mei, Chandra Verma, Long Zhang, Laila Ritsma, Peter ten DijkebioRxiv 2020 · DOI

TL;DR

This study reveals a surprising role for TRAF4 in bladder cancer, where its presence is associated with better patient survival, contrary to its known role in other cancers. TRAF4 appears to suppress aggressive, mesenchymal-like bladder cancer by promoting BMP/SMAD signaling and degrading the EMT-promoting protein SMURF1.

What Problem Does This Paper Address?

Bladder cancer is a significant health concern, often characterized by invasion and metastasis, leading to poor prognoses. While the protein TRAF4 is generally known as a tumor promoter in various cancers, its specific role in bladder cancer progression, particularly in the context of epithelial-to-mesenchymal transition (EMT) – a key process in metastasis – was unclear. This paper investigates how TRAF4 expression influences bladder cancer aggressiveness and patient survival, aiming to uncover its underlying mechanisms.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics and Patient Data Analysis: They analyzed publicly available bladder cancer patient data (TCGA) to correlate TRAF4 expression with overall survival and used immunohistochemistry on tissue microarrays to assess TRAF4 protein levels in different tumor stages.
  • Cell Line Studies: They utilized various bladder cancer cell lines (epithelial and mesenchymal) to investigate the effects of TRAF4 knockdown and overexpression.
  • Molecular Biology Techniques: This included:
  • Real-time PCR and Western Blotting: To measure mRNA and protein levels of TRAF4, EMT markers (E-cadherin, N-cadherin, Vimentin), and signaling pathway components (SMURF1, BMP/SMAD, NF-κB).
  • 5'-Azacytidine Treatment: To assess the role of epigenetic repression in TRAF4 expression.
  • Cycloheximide Chase Assays: To determine protein stability.
  • Site-Directed Mutagenesis and Mass Spectrometry: To identify and study post-translational modifications, specifically phosphorylation at Serine 334 (S334) by ERK kinase, and its impact on TRAF4 stability and localization.
  • Transcriptomic Analysis (RNA-seq): To identify global gene expression changes upon TRAF4 mis-expression and analyze pathway enrichment.
  • Ubiquitination Assays: To investigate TRAF4's role in targeting SMURF1 for degradation.
  • In vitro Assays: Transwell migration assays, wound-healing assays, and MTS assays were used to assess cell migration, invasion, and proliferation.
  • Molecular Modeling and Simulation: To understand the structural and electrostatic effects of S334 phosphorylation on TRAF4's interaction with PIP3 molecules and its plasma membrane localization.

Datasets

  • TCGA (The Cancer Genome Atlas) BLCA data: Used for correlating TRAF4 mRNA expression with overall survival.
  • Human Protein Atlas: Used for obtaining TCGA data.
  • Biomax U.S. tissue microarray samples (BL802b): Used for immunohistochemistry to assess TRAF4 protein levels in patient samples.
  • Publicly available data on 59 bladder cancer cell lines: Used for EMT scoring and correlation with TRAF4 expression.

Key Insights and Ideas

  • TRAF4 as a Tumor Suppressor in Bladder Cancer: This is the most striking finding, directly contradicting its established role in other cancers. The study suggests TRAF4's presence is beneficial for bladder cancer patients.
  • TRAF4's Role in Suppressing EMT: By downregulating TRAF4 in epithelial cells, the study observed a gain of mesenchymal markers and loss of epithelial integrity, indicating TRAF4 actively prevents EMT.
  • Epigenetic Repression and Post-Translational Modification: TRAF4 expression is not only epigenetically repressed in aggressive cells but also its protein stability is regulated by ERK-mediated phosphorylation at S334, which destabilizes the protein.
  • TRAF4 Targets SMURF1 for Degradation: TRAF4's mechanism involves targeting SMURF1, a known promoter of EMT, for proteasomal degradation, thereby inhibiting pro-metastatic signaling.
  • BMP/SMAD vs. NF-κB Signaling: TRAF4 promotes BMP/SMAD signaling (associated with better prognosis) and suppresses NF-κB signaling (associated with aggressive cancer).

Key Results

  • Survival Correlation: Lower TRAF4 expression was significantly associated with lower overall survival in bladder cancer patients.
  • EMT Status: Epithelial bladder cancer cells (less aggressive) showed higher TRAF4 expression compared to mesenchymal cells (more aggressive).
  • TRAF4 Knockdown: Led to increased expression of mesenchymal markers (N-cadherin, SLUG) and loss of epithelial integrity in epithelial cell lines.
  • TRAF4 Overexpression: In mesenchymal cells, it reduced migration and invasion.
  • SMURF1 Regulation: TRAF4 knockdown led to increased SMURF1 protein levels, while TRAF4 overexpression decreased them.
  • Signaling Pathway Modulation: TRAF4 overexpression enhanced BMP/SMAD signaling and dampened NF-κB signaling, which was confirmed in patient samples (positive correlation with pSMAD1/5/8, negative with p-p65).
  • S334 Phosphorylation: Phosphorylation of S334 by ERK kinase destabilizes TRAF4 and disrupts its plasma membrane localization, hindering its interaction with PIP3.

Limitations and Future Work

  • In vivo Relevance: While the study provides strong mechanistic insights, further validation in animal models would strengthen the findings.
  • Therapeutic Implications: The authors suggest that targeting SMURF1 or using BMP agonists in bladder cancers with low TRAF4 expression could be a promising therapeutic avenue. They also caution against the development of TRAF4 inhibitors due to its potentially beneficial role in bladder cancer.
  • ERK Pathway in Bladder Cancer: The study highlights the role of ERK signaling in TRAF4 regulation, suggesting further investigation into the MAPK pathway's involvement in bladder cancer progression.

Summary updated

Abstract

Abstract Bladder cancer is one of the most prevalent cancer types in the world, frequently exhibiting invasion and metastasis and therefore associated with poor prognosis. It is a progressive disease with high recurrence rates even after surgery, which calls for the urgent need for early intervention and diagnosis. The E3 ubiquitin ligase TNF Receptor Associated Factor 4 (TRAF4) has been largely implicated as a tumour-promoting element in a wide range of cancers. Over-expression and amplification of this gene product has been a common observation in breast and other metastatic tumours. In contrast, we observed that expression of TRAF4 negatively correlated with overall patient survival. Moreover, its expression was repressed at epigenetic levels in aggressive bladder cancer cells. We also describe an ERK kinase phosphorylation site on TRAF4 that inhibits its stability and localization to plasma membrane in such cells. Furthermore, knockdown of TRAF4 in epithelial bladder cancer cell lines leads to gain of mesenchymal genes and a loss of epithelial integrity. Reciprocally, stable over-expression of TRAF4 in mesenchymal cells leads to decreased migratory and invasive properties. Transcriptomic analysis upon TRAF4 mis-expression in bladder cancer cell lines revealed that higher TRAF4 expression enhanced BMP/SMAD and dampened NF-κB signalling pathways. Importantly, this notion was confirmed in bladder cancer patient material. Mechanistically, we showed that TRAF4 targets the E3 ubiquitin ligase SMURF1, a negative regulator of BMP/SMAD signalling, for proteasomal degradation in bladder cancer cells. We show that genetic and pharmacological inhibition of SMURF1 or its function inhibited migration of aggressive (mesenchymal) bladder cancer cells.
BibTeX
@misc{iyengar2020traf,
  author = {Prasanna Vasudevan Iyengar and Dieuwke L. Marvin and Dilraj Lama and Tuan Zea Tan and Sudha Suriyamurthy and Feng Xie and Maarten van Dinther and Hailiang Mei and Chandra Verma and Long Zhang and Laila Ritsma and Peter ten Dijke},
  title = {{TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway}},
  year = {2020},
  doi = {10.1101/2020.10.12.335588},
  howpublished = {bioRxiv},
}
Figure